Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12

Table 3 Characteristics of patients, who died during treatment, discontinued treatment prematurely, or suffered from virological relapse after end of treatment

	Age (yr)	Sex	BL viral load, IU/mL	GT	LCi	BL MELD	Previous treatment	Current treatment	Treatment duration	Cause for premature discontinuation	Outcome	RAV NS3 protease	RAV NS5A	RAV NS5B polymerase
Patients, who died during treatment, or discontinued treatment prematurely
No. 1	63	male	1.41 Mio	1b	Yes	12	PR	SOF/SMV	12	Sepsis	death
No. 2	66	male	1.69 Mio	1b	Yes, HTx	14	-	SOF/LDV	5	Intracranial bleeding	death
No. 3	55	male	56200	1b	Yes, LTx	24	TVR/PR	SOF/SMV/R	14	Re-LTx, sepsis	death
No. 4	49	male	157000	1a	Yes,	14	PR	SOF/LDV/R	8	Right-heart failure	death
No. 5	79	female	5.85 Mio	1b	Yes	6	TVR/PR	SOF/SMV	10	Back-pain	SVR 24
No. 6	55	male	396000	1a	Yes, TIPSS	10	PR	SOF/DCV	16	Hepatic encephalopathy	SVR 24
Patients with relapse after end of treatment
No. 7	54	male	10300	1a	Yes	8	PR	SOF/PR	12			NA	NA	NA
No. 8	63	male	321000	1b	-	6	-	SOF/PR	12			NA	NA	NA
No. 9	43	female	408000	1a	Yes	8	-	SOF/PR	12			NA	NA	NA
No. 10	40	male	2.74 Mio	1b	-	6	PR	SOF/PR	12			NA	NA	NA
No. 11	48	male	4.89 Mio	3a	No, LTx	11	PR	SOF/DCV/R	24			F43F/L	A30K	-
No. 12	56	female	1.38 Mio	3a	Yes	7	PR	SOF/DCV	24			-	Y93H	S282S/T
No. 13	38	male	3.39 Mio	1b	-	6	-	SOF/DCV	12			Q80K	L31M, Y93H	-
No. 14	52	male	2.47 Mio	3a	Yes	10	-	SOF/DCV/R	24			-	Y93H	-
No. 15	55	female	3.03 Mio	1a	-	6	TVR/PR	SOF/DCV	12			T54S, R155K	L31M/L	-
No. 16	49	male	8340	3	Yes	6	-	SOF/LDV/R	24			-	A30S	-
No. 17	52	male	239000	1b	Yes	6	-	SOF/LDV/R	12			T54S, V55I, Q80K	Q30E	-
No. 18	57	male	137 (on SOF/R)	1a	Yes, HCC	11	SOF/R	SOF/DCV	12			-	L31M, P58S, Y93C	-

BL: Baseline; GT: Genotype; HCC: Hepatocellular carcinoma; LCi: Liver cirrhosis; MELD: Model of end stage liver disease; P: Pegylated Interferon; R: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; DCV: Daclatasvir; TVR: Telaprevir; RAV: Resistance associated variant; HTx: Heart transplantation; LTx: Liver transplantation; TIPSS: Transjugular portosystemic stent shunt; NA: Not available.